Tri-lo-sprintec Kit
Product Images NDC 0093-2140

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tri-lo-sprintec (NDC 0093-2140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

An illustration showing a hand holding a day-of-the-week label strip above a 28-day pill blister pack for Tri-Lo-Sprintec, a triphasic oral contraceptive containing norgestimate and ethinyl estradiol. The blister pack is organized by day and week, with different colored tablets arranged in four rows representing four weeks of daily dosing.*

FDA Label Image

Image 2

A forest plot chart showing effect estimates (Odds Ratios/Relative Risks) with confidence intervals from multiple studies related to contraceptive use, including the NICHD Women's Contraceptive Study (2002), French E3N cohort Study (2005), Shanghai Women's Health Study (2009), Nurses' Health Studies, Oxford Family Planning Association Study (2013), and Danish Sex Hormone Register Study (2017). The x-axis measures the effect estimate ranging approximately from -1.5 to 2.0, with a vertical line at 1.0 indicating no effect.*

FDA Label Image

Image 3

Chemical structure diagrams of Norgestimate and Ethinyl Estradiol, identified by their molecular formulas and molecular weights (Norgestimate C23H31NO3, M.W. 369.50; Ethinyl Estradiol C20H24O2, M.W. 296.40), representing the active ingredients in the Tri-Lo-Sprintec kit.*

FDA Label Image

Image 4

An illustration diagram categorizing birth control methods by effectiveness in preventing pregnancies per 100 women per year. It ranges from fewer than 1 pregnancy (implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones) to more than 85 pregnancies (no birth control). Intermediate methods include condoms, diaphragm, spermicide, withdrawal, and no sex during fertile days.*

FDA Label Image

Image 5

Illustration showing a hand holding the Tri-Lo-Sprintec kit card containing a 28-day supply of norgestimate and ethinyl estradiol tablets in a triphasic regimen. The card displays tablets arranged by day of the week with shaded and unshaded circles representing the dosage sequence.*

FDA Label Image

Image 6

Packaging label for Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets USP) triphasic regimen kit by Teva Pharmaceuticals USA, Inc. The label indicates 3 blister cards with 28 tablets each for a 28-day regimen. It includes the NDC 0093-2140, storage instructions, and pharmacist information. The label features the Teva logo and the Shaping Women's Health logo.*

FDA Label Image

Image 7

Tri-Lo-Sprintec kit packaging label shows a triphasic oral contraceptive containing norgestimate and ethinyl estradiol tablets USP. The box states it contains 3 blister cards with 28 tablets each, sufficient for a 28-day regimen. The labeler is Teva Pharmaceuticals USA, Inc. The label also includes a warning that the product does not protect against HIV infection or sexually transmitted diseases.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.